Regenxbio Inc (NASDAQ: RGNX) on Friday, soared 2.60% from the previous trading day, before settling in for the closing price of $6.55. Within the past 52 weeks, RGNX’s price has moved between $5.62 and $23.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 111.76% annually for the last half of the decade. The company achieved an average annual earnings per share of 96.20%. With a float of $44.72 million, this company’s outstanding shares have now reached $49.53 million.
In an organization with 344 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 49.84%, operating margin of -277.51%, and the pretax margin is -272.54%.
Regenxbio Inc (RGNX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Regenxbio Inc is 9.75%, while institutional ownership is 87.22%. The most recent insider transaction that took place on Dec 30 ’24, was worth 148,504. Before that another transaction happened on Oct 01 ’24, when Company’s Director sold 10,000 for $10.11, making the entire transaction worth $101,052. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 96.20% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Regenxbio Inc (RGNX) is currently performing well based on its current performance indicators. A quick ratio of 3.05 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit 0.48 in the next quarter and is forecasted to reach -1.06 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.92 million. That was inferior than the volume of 0.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 71.44%. Additionally, its Average True Range was 0.54.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 16.67%, which indicates a significant decrease from 50.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.92% in the past 14 days, which was lower than the 75.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.32, while its 200-day Moving Average is $10.21. However, in the short run, Regenxbio Inc’s stock first resistance to watch stands at $7.49. Second resistance stands at $8.25. The third major resistance level sits at $8.69. If the price goes on to break the first support level at $6.29, it is likely to go to the next support level at $5.85. Assuming the price breaks the second support level, the third support level stands at $5.09.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
Market capitalization of the company is 336.58 million based on 49,545K outstanding shares. Right now, sales total 90,240 K and income totals -263,490 K. The company made 24,200 K in profit during its latest quarter, and -59,600 K in sales during its previous quarter.
